Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890218132> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W2890218132 abstract "e18515 Background: The outcome of genetically high risk acute myeloid leukemia (AML) patients (pts) remains poor, with a median overall survival (OS) of a few months after the failure of regimens. Long-term survival requires complete remission followed by allogeneic stem cell transplantation (ASCT).Clofarabine, a deoxyadenosine analog, at 20mg/m2 days 1-5, in combination with low-dose cytarabine (LDAC) has reported efficacy and tolerability in older newly diagnosed AML pts (Cancer 2015;121:2375). We have therefore prioritized this combination for relapsed/refractory(R/R) pts. Aims:Determine the efficacy of Clofarabine and low dose cytarabine in R/R AML pts who are eligible for ASCT. Methods: Using Holden Comprehensive Cancer Center database, we performed a retrospective chart review on 16 pts of R/R AML who were treated with Clofarabine and LDAC between January 2014 and Dec 2016. Each patient received Clofarabine 20mg/m 2 on days 1-5 IV and LDAC on days 1-10 subcutaneous. The primary endpoint was complete remission (CR) or complete remission with incomplete marrow recovery (CRi). Secondary endpoint was median OS. Results: Sixteen pts were analyzed. The median age was 58 years (range 27-78). Nine pts (56%) had AML with high risk characteristics (complex karyotype and/or presence of FLT3-ITD). Nine pts achieved either a CR or CRi. Responses were observed in 7of 9 pts with genetically high-risk features. 2 pts had mutated TP53, and both of them achieved CR. The median OS time was 13.25 months (range 3.6-19.2 months). 4 pts received ASCT after treatment combination. Conclusions: These results suggest that Clofarabine is well-tolerated and effective in the treatment of R/R AML pts, especially those with high-risk genetics. Clofarabine and LDAC could be used as a bridging therapy prior to ASCT for high-risk R/R AML pts. Future clinical trials are warranted to explore additional modifications to this combination in order to optimize therapy for this group of high-risk and heavily treated R/R AML pts." @default.
- W2890218132 created "2018-09-27" @default.
- W2890218132 creator A5004469646 @default.
- W2890218132 creator A5012245882 @default.
- W2890218132 creator A5021418221 @default.
- W2890218132 creator A5022206159 @default.
- W2890218132 creator A5052566782 @default.
- W2890218132 creator A5070140190 @default.
- W2890218132 creator A5086805182 @default.
- W2890218132 date "2017-05-20" @default.
- W2890218132 modified "2023-09-27" @default.
- W2890218132 title "Efficacy of clofarabine and low-dose cytarabine combination for genetically high-risk acute myeloid leukemia prior to allogeneic stem cell transplantation." @default.
- W2890218132 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e18515" @default.
- W2890218132 hasPublicationYear "2017" @default.
- W2890218132 type Work @default.
- W2890218132 sameAs 2890218132 @default.
- W2890218132 citedByCount "0" @default.
- W2890218132 crossrefType "journal-article" @default.
- W2890218132 hasAuthorship W2890218132A5004469646 @default.
- W2890218132 hasAuthorship W2890218132A5012245882 @default.
- W2890218132 hasAuthorship W2890218132A5021418221 @default.
- W2890218132 hasAuthorship W2890218132A5022206159 @default.
- W2890218132 hasAuthorship W2890218132A5052566782 @default.
- W2890218132 hasAuthorship W2890218132A5070140190 @default.
- W2890218132 hasAuthorship W2890218132A5086805182 @default.
- W2890218132 hasConcept C126322002 @default.
- W2890218132 hasConcept C143998085 @default.
- W2890218132 hasConcept C2777198975 @default.
- W2890218132 hasConcept C2778041864 @default.
- W2890218132 hasConcept C2778461978 @default.
- W2890218132 hasConcept C2778729363 @default.
- W2890218132 hasConcept C2779282312 @default.
- W2890218132 hasConcept C28328180 @default.
- W2890218132 hasConcept C2911091166 @default.
- W2890218132 hasConcept C54355233 @default.
- W2890218132 hasConcept C71924100 @default.
- W2890218132 hasConcept C86803240 @default.
- W2890218132 hasConceptScore W2890218132C126322002 @default.
- W2890218132 hasConceptScore W2890218132C143998085 @default.
- W2890218132 hasConceptScore W2890218132C2777198975 @default.
- W2890218132 hasConceptScore W2890218132C2778041864 @default.
- W2890218132 hasConceptScore W2890218132C2778461978 @default.
- W2890218132 hasConceptScore W2890218132C2778729363 @default.
- W2890218132 hasConceptScore W2890218132C2779282312 @default.
- W2890218132 hasConceptScore W2890218132C28328180 @default.
- W2890218132 hasConceptScore W2890218132C2911091166 @default.
- W2890218132 hasConceptScore W2890218132C54355233 @default.
- W2890218132 hasConceptScore W2890218132C71924100 @default.
- W2890218132 hasConceptScore W2890218132C86803240 @default.
- W2890218132 hasLocation W28902181321 @default.
- W2890218132 hasOpenAccess W2890218132 @default.
- W2890218132 hasPrimaryLocation W28902181321 @default.
- W2890218132 hasRelatedWork W1554385820 @default.
- W2890218132 hasRelatedWork W1995507278 @default.
- W2890218132 hasRelatedWork W2020198954 @default.
- W2890218132 hasRelatedWork W2027999020 @default.
- W2890218132 hasRelatedWork W2050003256 @default.
- W2890218132 hasRelatedWork W2056893592 @default.
- W2890218132 hasRelatedWork W2064992553 @default.
- W2890218132 hasRelatedWork W2132297795 @default.
- W2890218132 hasRelatedWork W2139674976 @default.
- W2890218132 hasRelatedWork W2146611052 @default.
- W2890218132 hasRelatedWork W2395435899 @default.
- W2890218132 hasRelatedWork W2601825657 @default.
- W2890218132 hasRelatedWork W2804600666 @default.
- W2890218132 hasRelatedWork W288699731 @default.
- W2890218132 hasRelatedWork W2945796624 @default.
- W2890218132 hasRelatedWork W2953580550 @default.
- W2890218132 hasRelatedWork W2987284328 @default.
- W2890218132 hasRelatedWork W3092097176 @default.
- W2890218132 hasRelatedWork W93525153 @default.
- W2890218132 hasRelatedWork W953711912 @default.
- W2890218132 isParatext "false" @default.
- W2890218132 isRetracted "false" @default.
- W2890218132 magId "2890218132" @default.
- W2890218132 workType "article" @default.